Coeptis Therapeutics (COEP) Short Interest Ratio & Short Volume

Short interest is the volume of Coeptis Therapeutics shares that have been sold short but have not yet been covered or closed out. As of February 15th, investors have sold 13,800 shares of COEP short. 0.52% of Coeptis Therapeutics' shares are currently sold short. Learn More on Coeptis Therapeutics' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.52% of Coeptis Therapeutics' floating shares are currently sold short.

Coeptis Therapeutics saw a drop in short interest in February. As of February 15th, there was short interest totaling 13,800 shares, a drop of 34.3% from the previous total of 21,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Coeptis Therapeutics currently has issued a total of 3,242,000 shares. Some of Coeptis Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Coeptis Therapeutics currently has a public float of 2,630,000 shares.

0.52% of Coeptis Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Coeptis Therapeutics: Zentalis Pharmaceuticals, Inc. (7.55%), Organigram Holdings Inc. (4.76%), Adaptimmune Therapeutics plc (3.21%), Silence Therapeutics plc (4.78%), 2seventy bio, Inc. (10.90%), Seres Therapeutics, Inc. (10.92%), Genelux Co. (7.66%), Checkpoint Therapeutics, Inc. (20.84%), Coya Therapeutics, Inc. (1.67%), Telomir Pharmaceuticals, Inc. (10.05%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($25.81 billion), iShares 20+ Year Treasury Bond ETF ($10.38 billion), MicroStrategy Incorporated ($7.74 billion), AppLovin Co. ($6.32 billion), Apollo Global Management, Inc. ($5.97 billion), Super Micro Computer, Inc. ($4.89 billion), Charter Communications, Inc. ($4.52 billion), Capital One Financial Co. ($3.94 billion), Schlumberger Limited ($3.19 billion), and Reddit, Inc. ($3.01 billion). View all of the most shorted stocks.

Short selling COEP is an investing strategy that aims to generate trading profit from Coeptis Therapeutics as its price is falling. COEP shares are trading up $0.34 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Coeptis Therapeutics occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of COEP, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including COEP, twice per month. The most recent reporting period available is February, 15 2025.